2020 JULY NRG MEETING Minesh Mehta Mark Gilbert
2020 JULY NRG MEETING Minesh Mehta, Mark Gilbert, Michael Vogelbaum, Arnab Chakravarti, Mei Polley
CONCEPTS FOR DISCUSSION (RSC) Trial (n)/PI Target Population Status/Comments Burri BM Pre vs. post-op SRS Sperduto/Kotecha Melanoma BM ICIs + SRS vs. FSRT Puduvalli/Gondi Adult Medullo EORTC Concept
CONCEPTS IN DISCUSSION Trial (n)/PI Target Population Status/Comments Rimas GBM unmeth RT + IDO Kim GBM Advanced imaging based RT Sengupta Meningioma Mebendazole Umemura GBM Dual viral vector Aulakh GBM Daratumumab; PRIDE
NRG GBM PORTFOLIO Trial (n)/PI Target Population Status/Comments BN 001 (193)/Mehta n. GBM Active. 147; protons only; 9/22 closure BN 007 (750)/Lassman n. GBM, unmethylated OEWG absolute 8/2020 BN 010 (13 -55)/Bagley r. GBM OEWG absolute 1/2021; GNE/NCI supportive of requesting extension due to COVID/drug availability and transition from ABTC BN 1932 (308)/Iwamoto n. GBM, methylated Approved by NRG RSC 5/2019. BMSC submission timeline needed. EAF 151 (165) r. GBM Active. Non-therapeutic. ECOG-ACRIN NCORP study w/ NRG champion. IDO concept (? )/Lukas n. GBM, unmethylated In development for presentation to future NRG RSC. n. GBM In development for possible presentation to NRG RSC. Candel GMCI) Therapeutics Denovo TOCA/Ahluwalia (P 3 n. GBM perioperative Former BN 006; under discussion as redesign to RTOGf.
NRG METS PORTFOLIO Trial (n)/PI Target Population Status/Comments CE 7 (206)/Roberge 5 -15 mets Active (CCTG lead). 28; SRS vs. WBRT (HA) A 071801 (208)/Brown Post-op met Active (Alliance lead). 13; SRS vs. FSRS BN 009 (187/312)/Gondi+CR Post-SRS r. Met Protocol in development. OEWG absolute 3/2021; should activate earlier CC 003 (302)/Gondi SCLC PCI Active (NCORP) 304; WBRT vs. HAWBRT; amend to increase accrual CC 009/Gondi SCLC BM <10 Protocol in development (NCORP). OEWG target 5/2021; HA WBRT vs. SRS BN 1943 redesign Melanoma BM (to be renumbered)/ Sperduto Concept to be reviewed by RSC Jul 2020. ICI + SRS vs. SRT. NSCLC concept/Li+Gondi NSCLC BM Developing concept under discussion. ICI + SRS vs. SRT. Discuss after BN 1943 outcome Breast BM--- Developing concept under discussion. ICI + SRS vs. SRT. Discuss after BN 1943 Breast Kharsaw/Knisley met concept
NRG LOWER GRADE GLIOMA PORTFOLIO Trial (n)/PI Target Population Status/Comments BN 005 (120)/Grosshans IDHmut glioma Active. Proton vs. photon, 32 enrolled 1071 (360)/Lassman G 2/3 glioma Active (NCCTG lead). TMZ vs. PCV, 187 enrolled (CODEL) NRG OTHER TUMORS PORTFOLIO Trial (n)/PI Target Population Status/Comments BN 003 (133)/Rogers G 2 Meningioma Active. 79; RT vs Obs G 2/3 Meningioma/Kruser RT+ICI Preliminary concept; needs work PCNSL +/- Ibritunib RTOGf; concept under review by HQ & PCYC
Investigator Resources § Ancillary Projects / Data Sharing – Data can be requested for analyses not specified in the protocol. Projects can include the NRG statistician for the analysis or be done with investigator’s approved statistician. § Application & List of Approved Projects https: //www. nrgoncology. org/Resources/Ancillary-Projects-Data-Sharing-Application § Biospecimen Access – How to request access to NRG biospecimens for studies deposited in the NCI Navigator or held by the NRG bank https: //www. nrgoncology. org/Scientific-Program/Biospecimen-Access § Cancer Atlases, Templates, & Tools https: //www. nrgoncology. org/About-Us/Center-for-Innovation-in-Radiation-Oncology § Publication Guidelines & Database https: //www. nrgoncology. org/Clinical-Trials/Publications § New Investigator Liaison Contact – Vinai Gondi, MD
- Slides: 7